CRBU Q2 2023 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-10.4% YoY

Gross Profit

-$23M-605.8% margin

Operating Income

-$33M-875.3% margin

Net Income

-$30M-786.1% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$18M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$350M

Total Liabilities

$80M

Stockholders' Equity

$269M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$4M	-10.4%
Gross Profit	-$23M	-$18M	-23.7%
Operating Income	-$33M	-$28M	-15.6%
Net Income	-$30M	-$27M	-10.6%

Geographic Segments

UNITED STATES

$4M100%

Non-US

$9,0000%